LVTX · Lava Therapeutics
Acquired Company
XOMA Royalty completed the acquisition of LAVA Therapeutics N.V. (LVTX) on 11/21/2025, acquiring all outstanding common shares for $1.04 per share in cash plus a non-transferable contingent value right (CVR).
Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands.
YALELAAN 62, UTRECHT, NETHERLANDS, 3584 CM, Utrecht, 3584 CM, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
45.77M
52 Wk Range
$0.94 - $1.82
Previous Close
$1.74
Open
$1.74
Volume
N/A
Day Range
$1.74 - $1.74
Enterprise Value
-3.893M
Cash
49.66M
Avg Qtr Burn
-4.868M
Insider Ownership
16.39%
Institutional Own.
27.54%
Qtr Updated
Sep 30th 2025